| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f6302e19ea0b27b764fe9a3f539b8c4e |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y304-21021
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y304-21006
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y304-21022
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P39-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-4846
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-745
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-745 |
| filingDate |
2014-05-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fe41c55757b2980cf2f76fae9e2a3e2f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_527c107fe59fc9abdb23e169d5f14ee3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_342e208307936f1d4ea590e70eb98566
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e9026a82060019487252d148af4919d3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_58dd28fa4bf4923787126452ed646d96 |
| publicationDate |
2016-04-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3006461-A1 |
| titleOfInvention |
Human coagulation factor light-chain protein and application of same |
| abstract |
In the invention, the minimum inhibitory concentrations of human coagulation factor light-chain proteins against different Gram-negative bacteria are detected with the in vitro antibacterial activity and the inhibiting effect of the human coagulation factor light-chain proteins against different Gram-negative bacteria is detected with the in vivo antibacterial activity. It has been shown that human coagulation factor light-chain proteins have an obvious inhibitory effect on the Gram-negative bacteria, so as to develop a novel class of medicaments for treating Gram-negative bacteria infection. It has been demonstrated by mass spectrometry and silver staining that human coagulation factor light-chain proteins have the effect on hydrolyzing and eliminating the endotoxin, which facilitates the development of a novel class of medicaments for treating endotoxemia. The human coagulation factor light-chain proteins are light chain proteins of human coagulation factors VII, IX, and X, as well as a protein having homology of more than 50% thereof. |
| priorityDate |
2013-05-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |